Menu
Search
|

Menu

Close
X

Pieris Pharmaceuticals Inc PIRS.OQ (NASDAQ Stock Exchange Capital Market)

5.08 USD
-- (--)
As of Oct 15
chart
Previous Close 5.08
Open --
Volume --
3m Avg Volume 118,944
Today’s High --
Today’s Low --
52 Week High 9.69
52 Week Low 4.44
Shares Outstanding (mil) 54.03
Market Capitalization (mil) 272.88
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.57 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY18
16
FY17
25
FY16
6
FY15
3
EPS (USD)
FY18
-0.178
FY17
-0.410
FY16
-0.545
FY15
-0.420
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.14
Price to Sales (TTM)
vs sector
7.20
6.55
Price to Book (MRQ)
vs sector
4.93
4.00
Price to Cash Flow (TTM)
vs sector
--
21.51
Total Debt to Equity (MRQ)
vs sector
0.00
14.15
LT Debt to Equity (MRQ)
vs sector
0.00
11.31
Return on Investment (TTM)
vs sector
-9.44
12.83
Return on Equity (TTM)
vs sector
-26.25
14.95

EXECUTIVE LEADERSHIP

James Geraghty
Chairman of the Board, Since 2017
Salary: --
Bonus: --
Stephen Yoder
President, Chief Executive Officer, Director, Since 2014
Salary: $266,222.00
Bonus: $54,455.00
Lance Thibault
Acting Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Claude Knopf
Senior Vice President, Chief Business Officer, Since 2016
Salary: --
Bonus: --
Louis Matis
Senior Vice President and Chief Development Officer, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

255 State St Fl 9
BOSTON   MA   02109-2615

Phone: +1857.2468998

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company's second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.

SPONSORED STORIES